STOCK TITAN
  1. Home
  2. Sec-filings
  3. PAHC
  4. [Form 4] PHIBRO ANIMAL HEALTH CORP Insider Trading Activity

Insider sales at Phibro Animal Health (PAHC) under 10b5-1 plan trades

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Phibro Animal Health Corporation insider activity centers on BFI Co., LLC, an entity associated with President and CEO Jack Bendheim. On January 13, 2026, BFI sold 7,551 shares of Class A common stock at a weighted average price of $40.3154 under a Rule 10b5-1 trading plan. On January 14, 2026, BFI converted 20,000 shares of Class B common stock into 20,000 shares of Class A at a conversion price of $0, then sold 3,258 shares at a weighted average price of $40.4592 and 393 shares at $41.1375. On January 15, 2026, BFI sold an additional 2,932 shares at a weighted average price of $40.0233. Following these transactions, BFI indirectly holds 44,525 shares of Class A common stock and 19,941,034 shares of Class B common stock, while Jack Bendheim directly holds 16,840 shares of Class A common stock.

Positive

  • None.

Negative

  • None.
Insider BENDHEIM JACK, BFI Co., LLC
Role President and CEO | 10% Owner
Sold 14,134 shs ($570K)
Type Security Shares Price Value
Sale Class A Common Stock 2,932 $40.0233 $117K
Conversion Class B Common Stock 20,000 $0.00 --
Conversion Class A Common Stock 20,000 $0.00 --
Sale Class A Common Stock 3,258 $40.4592 $132K
Sale Class A Common Stock 393 $41.1375 $16K
Sale Class A Common Stock 7,551 $40.3154 $304K
holding Class A Common Stock -- -- --
Holdings After Transaction: Class A Common Stock — 44,525 shares (Indirect, See); Class B Common Stock — 19,941,034 shares (Indirect, See); Class A Common Stock — 16,840 shares (Direct)
Footnotes (1)
  1. The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.09 to $40.51. The Reporting Person undertakes to provide to Phibro Animal Health Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote and in footnotes 5, 6 and 7. The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis, at the holder's election, and has no expiration date. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.025 to $40.985. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.125 to $41.15. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.07. The reported securities are directly held by Jack Bendheim.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
BENDHEIM JACK
(Last) (First) (Middle)
300 FRANK W. BURR BLVD., STE 21
(Street)
TEANECK NJ 07666
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
PHIBRO ANIMAL HEALTH CORP [ PAHC ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director X 10% Owner
X Officer (give title below) Other (specify below)
President and CEO
3. Date of Earliest Transaction (Month/Day/Year)
01/13/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
X Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Class A Common Stock 01/13/2026 S(1) 7,551 D $40.3154(2) 31,108 I See(3)
Class A Common Stock 01/14/2026 C(4) 20,000 A $0 51,108 I See(3)
Class A Common Stock 01/14/2026 S(1) 3,258 D $40.4592(5) 47,850 I See(3)
Class A Common Stock 01/14/2026 S(1) 393 D $41.1375(6) 47,457 I See(3)
Class A Common Stock 01/15/2026 S(1) 2,932 D $40.0233(7) 44,525 I See(3)
Class A Common Stock 16,840 D(8)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Class B Common Stock $0 01/14/2026 C 20,000 (4) (4) Class A Common Stock 20,000 $0 19,941,034 I See(3)
1. Name and Address of Reporting Person*
BENDHEIM JACK
(Last) (First) (Middle)
300 FRANK W. BURR BLVD., STE 21
(Street)
TEANECK NJ 07666
(City) (State) (Zip)
Relationship of Reporting Person(s) to Issuer
X Director X 10% Owner
X Officer (give title below) Other (specify below)
President and CEO
1. Name and Address of Reporting Person*
BFI Co., LLC
(Last) (First) (Middle)
300 FRANK W. BURR BLVD., STE 21
(Street)
TEANECK NJ 07666
(City) (State) (Zip)
Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
Explanation of Responses:
1. The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025.
2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.09 to $40.51. The Reporting Person undertakes to provide to Phibro Animal Health Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote and in footnotes 5, 6 and 7.
3. The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
4. Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis, at the holder's election, and has no expiration date.
5. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.025 to $40.985.
6. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.125 to $41.15.
7. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.07.
8. The reported securities are directly held by Jack Bendheim.
/s/ Judith Weinstein, as Attorney-in-Fact for Jack Bendheim 01/15/2026
/s/ Judith Weinstein, as Attorney-in-Fact for BFI Co., LLC 01/15/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions were reported for PAHC on this Form 4?

The Form 4 reports that BFI Co., LLC, an entity associated with Phibro Animal Health, sold multiple blocks of Class A common stock on January 13–15, 2026 and converted 20,000 shares of Class B common stock into 20,000 shares of Class A common stock.

Who is the reporting insider for Phibro Animal Health (PAHC) on this Form 4?

The reporting persons are Jack Bendheim, who is a director, President and CEO, and 10% owner of Phibro Animal Health Corporation, and BFI Co., LLC, which is reported as a 10% owner. The reported securities in the main transactions are held by BFI Co., LLC.

Were the PAHC share sales made under a Rule 10b5-1 trading plan?

Yes. A footnote states that the reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC on May 30, 2025.

What were the sizes and prices of the PAHC Class A share sales?

BFI Co., LLC sold 7,551 shares on January 13, 2026 at a weighted average price of $40.3154, 3,258 shares on January 14, 2026 at $40.4592, 393 shares on the same date at $41.1375, and 2,932 shares on January 15, 2026 at $40.0233, each described as weighted average prices.

How many PAHC shares does BFI Co., LLC hold after these transactions?

After the reported transactions, BFI Co., LLC indirectly holds 44,525 shares of Class A common stock and 19,941,034 shares of Class B common stock, with the Class B being convertible into Class A on a one-for-one basis with no expiration date.

What PAHC shares are held directly by Jack Bendheim after these transactions?

A footnote states that 16,840 shares of Class A common stock are directly held by Jack Bendheim, separate from the shares held by BFI Co., LLC.

What is the relationship between Jack Bendheim and BFI Co., LLC in this Form 4?

The filing explains that the reported securities are directly held by BFI Co., LLC, and that Jack Bendheim exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over its holdings, while disclaiming beneficial ownership except to the extent of his pecuniary interest.